Corporate News Releases

ZyVersa Therapeutics Enhances Scientific Advisory Board with Three Esteemed Nephrologists
Jules A. Müsing, Former Senior Executive at Johnson & Johnson, Has Been Appointed Chairman of ZyVersa Therapeutics' Board of Directors
Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Variant Pharmaceuticals Submits Application for U.S. Orphan Drug Designation for VAR 200 (2-Hydroxypropyl-β-Cyclodextrin) To Treat Focal Segmental Glomerulosclerosis (FSGS)
Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-β-Cyclodextrin (2HPβCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)
Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-β-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS)
Variant Pharmaceuticals Enhances Its Board of Directors with Three New Members
Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease